Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans’ Trips And More
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the first two…
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA)…
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three…
Optimi To Supply Psilocybin For New Zealand’s Mātai Medical Research Institute
Canadian licensed psychedelics pharmaceutical manufacturer Optimi Health Corp. (OTCQX:OPTHF) has signed an international agreement to supply natural psilocybin…
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation…
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two…
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta’s Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have…
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full…
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a…
PharmAla’s Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the…